nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

09.07.2021 | Original Article

Increased uptake of ⁶⁸Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond

verfasst von: Chunxia Qin, Yangmeihui Song, Xi Liu, Yongkang Gai, Qingyao Liu, Weiwei Ruan, Fang Liu, Fan Hu, Xiaoli Lan

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe the uptake of ⁶⁸Gallium-labelled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) in the bones and joints for better understanding of the role of ⁶⁸Ga-FAPI PET in benign and malignant bone lesions and joint diseases.

Methods

All 129 ⁶⁸Ga-FAPI PET/MR or PET/CT scans from June 1, 2020, to February 20, 2021, performed at our PET center were retrospectively reviewed. Foci of elevated ⁶⁸Ga-FAPI uptake in the bones and joints were identified. All lesions were divided into malignant and benign diseases. Benign lesions included osteofibrous dysplasia, periodontitis, degenerative bone diseases, arthritis, and other inflammatory or trauma-related abnormalities. The number, locations, and SUVmax of all lesions were recorded and analyzed. The detectability of ⁶⁸Ga-FAPI PET and ¹⁸F-FDG PET in patients who had two scans was also compared.

Results

Elevated uptake of ⁶⁸Ga-FAPI in/around the bones and joints was found in 82 cases (63.57%). A total of 295 lesions were identified, including 94 (31.9%) malignant lesions (all were metastases) and 201 (68.1%) benign lesions. The benign lesions consisted of 13 osteofibrous dysplasia, 48 degenerative bone disease, 33 periodontitis, 56 arthritis, and 51 other inflammatory or trauma-related abnormalities. The spine, shoulder joint, alveolar ridge, and pelvis were the most commonly involved locations. Bone metastases were mainly distributed in the spine, pelvis, and ribs. Among benign diseases, periodontitis and arthritis are site-specific. The mean SUVmax of bone metastases was significantly higher than that of benign diseases (7.14 ± 4.33 vs. 3.57 ± 1.60, p < 0.001), but overlap existed. The differences in SUVmax among subgroups of benign diseases were statistically significant (p < 0.001), with much higher uptake in periodontitis (4.45 ± 1.17). ⁶⁸Ga-FAPI PET identified much more lesions than ¹⁸F-FDG PET (104 vs. 48) with higher uptake value.

Conclusion

⁶⁸Ga-FAPI accumulated in both bone metastases and some benign diseases of the bones and joints. Although the uptake of ⁶⁸Ga-FAPI was often higher in bone metastases, this finding cannot be used to distinguish between benign and malignant lesions. ⁶⁸Ga-FAPI PET also has the potential to locate and evaluate the extent of both malignant tumor and benign diseases in bones and joints.

Trial registration

NCT04554719, NCT04605939. Registered September 8, 2020 and October 25, 2020—retrospectively registered, http://clinicaltrails.gov/show/NCT04554719; http://clinicaltrails.gov/show/NCT04605939

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22. https://doi.org/10.2967/jnumed.118.210443.CrossRefPubMed

Mersmann M, Schmidt A, Rippmann JF, Wüest T, Brocks B, Rettig WJ, et al. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas. Int J Cancer. 2001;92:240–8. https://doi.org/10.1002/1097-0215(200102)9999:9999<::aid-ijc1170>3.0.co;2-u

Calais J. FAP: The next billion dollar nuclear theranostics target? J Nucl Med. 2020;61:163–5. https://doi.org/10.2967/jnumed.119.241232.CrossRefPubMed

Lindner T, Altmann A, Krämer S, Kleist C, Loktev A, Kratochwil C, et al. Design and Development of (99m)Tc-Labeled FAPI tracers for SPECT imaging and (188)Re therapy. J Nucl Med. 2020;61:1507–13. https://doi.org/10.2967/jnumed.119.239731.CrossRefPubMedPubMedCentral

Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an (18)F-labeled FAP inhibitor. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2020. https://doi.org/10.2967/jnumed.120.242958.

Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu and (225)Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019. https://doi.org/10.2967/jnumed.119.233122.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92. https://doi.org/10.2967/jnumed.118.215913.CrossRefPubMedPubMedCentral

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9. https://doi.org/10.2967/jnumed.118.210435.CrossRefPubMedPubMedCentral

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5. https://doi.org/10.2967/jnumed.119.227967.CrossRefPubMedPubMedCentral

10.

Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, et al. Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393–402. https://doi.org/10.1148/radiol.2020203275.CrossRefPubMed

11.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32. https://doi.org/10.1007/s00259-020-04769-z.CrossRefPubMed

12.

Sharma P, Singh SS, Gayana S. Fibroblast activation protein inhibitor PET/CT: a promising molecular imaging tool. Clin Nucl Med. 2021;46:e141–50. https://doi.org/10.1097/rlu.0000000000003489.CrossRefPubMed

13.

Zhuravlev F. Theranostic radiopharmaceuticals targeting cancer-associated fibroblasts. Curr Radiopharm. 2020. https://doi.org/10.2174/1874471013666201224114148.CrossRef

14.

Qin C, Gai Y, Liu Q, Shao F, Lan X. Elevated 68Ga-FAPI accumulation in a recurrent angiomyolipoma. Clin Nucl Med. 2020;45:1034–5. https://doi.org/10.1097/rlu.0000000000003345.CrossRefPubMed

15.

Wang R, Liu Q, Sui H, Zhang M, Zhu Z, Cui R. (68)Ga-FAPI outperforms (18)F-FDG PET/CT in identifying solitary fibrous tumor. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-05181-3.CrossRefPubMedPubMedCentral

16.

Liu H, Liu L, Chen L, Zhao Y, Zhang W, Cai L, et al. [(68)Ga]Ga-DOTA-FAPI-04 PET/CT imaging of benign pulmonary solitary fibrous tumour. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05199-1.CrossRefPubMedPubMedCentral

17.

Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79:1485–91. https://doi.org/10.1136/annrheumdis-2020-217408.CrossRefPubMed

18.

Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13: e010628. https://doi.org/10.1161/circimaging.120.010628.CrossRefPubMedPubMedCentral

19.

Pan Q, Luo Y, Zhang W. Idiopathic retroperitoneal fibrosis with intense uptake of 68Ga-fibroblast activation protein inhibitor and 18F-FDG. Clin Nucl Med. 2021;46:175–6. https://doi.org/10.1097/rlu.0000000000003402.CrossRefPubMed

20.

Zhou Y, He J, Chen Y. (68)Ga-FAPI PET/CT imaging in a patient with thyroiditis. Endocrine. 2021. https://doi.org/10.1007/s12020-021-02605-4.CrossRefPubMedPubMedCentral

21.

Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein targeted PET/CT with (68)Ga-FAPI for imaging IgG4-related disease: comparison to (18)F-FDG PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2020. https://doi.org/10.2967/jnumed.120.244723.

22.

Pang Y, Hao B, Shang Q, Sun L, Chen H. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a patient with cholangiocellular carcinoma: a case report. Clin Nucl Med. 2020;45:566–7. https://doi.org/10.1097/rlu.0000000000003056.CrossRefPubMed

23.

Pang Y, Huang H, Fu L, Zhao L, Chen H. 68Ga-FAPI PET/CT detects gastric signet-ring cell carcinoma in a patient previously treated for prostate cancer. Clin Nucl Med. 2020;45:632–5. https://doi.org/10.1097/rlu.0000000000003099.CrossRefPubMed

24.

Pang Y, Zhao L, Chen H. 68Ga-FAPI outperforms 18F-FDG PET/CT in identifying bone metastasis and peritoneal carcinomatosis in a patient with metastatic breast cancer. Clin Nucl Med. 2020;45:913–5. https://doi.org/10.1097/rlu.0000000000003263.CrossRefPubMed

25.

Xu T, Zhao Y, Ding H, Cai L, Zhou Z, Song Z, et al. [(68)Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05028-x.CrossRefPubMedPubMedCentral

26.

Liu H, Wang Y, Zhang W, Cai L, Chen Y. Elevated [(68)Ga]Ga-DOTA-FAPI-04 activity in degenerative osteophyte in a patient with lung cancer. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-05090-5.CrossRefPubMedPubMedCentral

27.

Tang YH, Yue ZS, Zheng WJ, Shen HF, Zeng LR, Hu ZQ, et al. 4-Phenylbutyric acid presents therapeutic effect on osteoarthritis via inhibiting cell apoptosis and inflammatory response induced by endoplasmic reticulum stress. Biotechnol Appl Biochem. 2018;65:540–6. https://doi.org/10.1002/bab.1642.CrossRefPubMed

28.

Lv FJ, Peng Y, Lim FL, Sun Y, Lv M, Zhou L, et al. Matrix metalloproteinase 12 is an indicator of intervertebral disc degeneration co-expressed with fibrotic markers. Osteoarthritis Cartilage. 2016;24:1826–36. https://doi.org/10.1016/j.joca.2016.05.012.CrossRefPubMed

29.

Croft AP, Campos J, Jansen K, Turner JD, Marshall J, Attar M, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019;570:246–51. https://doi.org/10.1038/s41586-019-1263-7.CrossRefPubMedPubMedCentral

30.

Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8:R171. https://doi.org/10.1186/ar2080.CrossRefPubMedPubMedCentral

31.

Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160–7. https://doi.org/10.2967/jnumed.120.244806.CrossRefPubMed

32.

Lukaszewski B, Nazar J, Goch M, Lukaszewska M, Stepinski A, Jurczyk MU. Diagnostic methods for detection of bone metastases. Contemp Oncol. 2017;21:98–103. https://doi.org/10.5114/wo.2017.68617.CrossRef

33.

Aisen AM, Martel W, Braunstein EM, McMillin KI, Phillips WA, Kling TF. MRI and CT evaluation of primary bone and soft-tissue tumors. AJR Am J Roentgenol. 1986;146:749–56. https://doi.org/10.2214/ajr.146.4.749.CrossRefPubMed

34.

Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, et al. The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2020. https://doi.org/10.2967/jnumed.119.237016

35.

Windisch P, Zwahlen DR, Koerber SA, Giesel FL, Debus J, Haberkorn U, et al. Clinical results of fibroblast activation protein (FAP) specific PET and implications for radiotherapy planning: systematic review. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12092629

36.

Song Y, Qin C, Liu F, Lan X. Fibrous dysplasia mimicking skeletal metastasis on 68Ga-FAPI PET imaging. Clin Nucl Med. 2021. https://doi.org/10.1097/rlu.0000000000003671.CrossRefPubMed

37.

Siebermair J, Köhler MI, Kupusovic J, Nekolla SG, Kessler L, Ferdinandus J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02307-w.CrossRefPubMedPubMedCentral

38.

Xing HQ, Gong JN, Chen BX, Guo XJ, Yang YH, Huo L, et al. Comparison of (68)Ga-FAPI imaging and cardiac magnetic resonance in detection of myocardial fibrosis in a patient with chronic thromboembolic pulmonary hypertension. J Nucl Cardiol. 2021. https://doi.org/10.1007/s12350-020-02517-2.CrossRefPubMed

39.

Qin C, Yang L, Ruan W, Shao F, Lan X. Immunoglobulin G4-related sclerosing cholangitis revealed by 68Ga-FAPI PET/MR. Clin Nucl Med. 2021;46:419–21. https://doi.org/10.1097/RLU.0000000000003552.CrossRefPubMed

40.

DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. The Journal of bone and joint surgery American volume. 2005;87:1848–64. https://doi.org/10.2106/jbjs.d.02942.

41.

Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Robey PG. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Investig. 1998;101:1737–44. https://doi.org/10.1172/jci2361.CrossRefPubMedPubMedCentral

42.

Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis. 2019;14:139. https://doi.org/10.1186/s13023-019-1102-9.CrossRefPubMedPubMedCentral

43.

Smith PC, Martinez C, Martinez J, McCulloch CA. Role of fibroblast populations in periodontal wound healing and tissue remodeling. Front Physiol. 2019;10:270. https://doi.org/10.3389/fphys.2019.00270.CrossRefPubMedPubMedCentral

44.

Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, et al. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology. 2009;55:432–40. https://doi.org/10.1111/j.1365-2559.2009.03399.x.CrossRefPubMedPubMedCentral

45.

Matyas JR, Sandell LJ, Adams ME. Gene expression of type II collagens in chondro-osteophytes in experimental osteoarthritis. Osteoarthritis Cartilage. 1997;5:99–105. https://doi.org/10.1016/s1063-4584(97)80003-9.CrossRefPubMed

46.

van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartilage. 2007;15:237–44. https://doi.org/10.1016/j.joca.2006.11.006.CrossRefPubMed

Titel: Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond
verfasst von: Chunxia Qin
Yangmeihui Song
Xi Liu
Yongkang Gai
Qingyao Liu
Weiwei Ruan
Fang Liu
Fan Hu
Xiaoli Lan
Publikationsdatum: 09.07.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05472-3

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Abdominal obesity, and not general obesity, is associated with a lower 123I MIBG heart-to-mediastinum ratio in heart failure patients with preserved ejection fraction

68Ga-PSMA and 68Ga-DOTATOC PET/CT imaging mismatch of primary pancreatic adenocarcinoma in prostate cancer patient

The ICPO Foundation—on the way toward collaborative growth of theranostics

Combination of whole body [18F]FDG PET angiography and PET/CT for giant cell arteritis

AI-enhanced simultaneous multiparametric 18F-FDG PET/MRI for accurate breast cancer diagnosis

A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET